Eli Lilly and Company has reappointed Nobel laureate Carolyn R. Bertozzi, Ph.D., to its Board of Directors, effective December 8, 2025. She will contribute to the Science and Technology Committee as well as the Ethics and Compliance Committee.
Welcoming her return, Lilly chair and CEO David A. Ricks said, “We are pleased to have Carolyn back at Lilly. As a Nobel Prize–winning chemist whose pioneering work has reshaped approaches to targeted therapeutics especially in cancer her insights will be crucial as we advance our oncology and immunology pipeline.”
Dr. Bertozzi is currently the Baker Family Director of Sarafan ChEM-H, and the Anne T. and Robert M. Bass Professor in Stanford University’s School of Humanities and Sciences. She also holds courtesy appointments in Chemical and Systems Biology and in Radiology, and serves as a Howard Hughes Medical Institute Investigator.
Her scientific contributions have earned numerous distinguished awards, and she is a member of the National Academy of Medicine, the National Academy of Sciences, and the American Academy of Arts and Sciences.
Bertozzi previously served on Lilly’s board from 2017 to 2021.
